Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anemia, Hemolytic, Congenital Nonspherocytic | 26 | 2024 | 56 | 13.030 |
Why?
|
Pyruvate Metabolism, Inborn Errors | 25 | 2024 | 50 | 11.980 |
Why?
|
Pyruvate Kinase | 28 | 2024 | 192 | 10.500 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 31 | 2024 | 245 | 8.490 |
Why?
|
Thrombocytopenia | 14 | 2022 | 1172 | 2.940 |
Why?
|
Anemia, Hemolytic, Autoimmune | 6 | 2021 | 147 | 1.710 |
Why?
|
Hematology | 4 | 2024 | 243 | 1.440 |
Why?
|
Anemia, Hemolytic | 2 | 2023 | 164 | 1.170 |
Why?
|
Erythrocyte Transfusion | 4 | 2020 | 574 | 1.140 |
Why?
|
Iron Overload | 6 | 2024 | 245 | 1.130 |
Why?
|
Rho(D) Immune Globulin | 3 | 2019 | 34 | 1.100 |
Why?
|
Hemorrhage | 10 | 2022 | 3464 | 0.880 |
Why?
|
Splenectomy | 6 | 2024 | 390 | 0.870 |
Why?
|
Benzoates | 6 | 2021 | 213 | 0.860 |
Why?
|
Quality of Life | 15 | 2024 | 13476 | 0.860 |
Why?
|
Leukopenia | 1 | 2022 | 213 | 0.770 |
Why?
|
Quinolines | 4 | 2024 | 769 | 0.770 |
Why?
|
Spherocytosis, Hereditary | 2 | 2014 | 83 | 0.770 |
Why?
|
Immunoglobulins, Intravenous | 5 | 2019 | 668 | 0.750 |
Why?
|
Platelet Count | 10 | 2021 | 784 | 0.720 |
Why?
|
Thrombopoietin | 3 | 2021 | 225 | 0.710 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2020 | 53 | 0.700 |
Why?
|
Child | 44 | 2024 | 80668 | 0.680 |
Why?
|
Hydrazines | 5 | 2021 | 223 | 0.680 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.670 |
Why?
|
Genetic Association Studies | 2 | 2020 | 2746 | 0.660 |
Why?
|
Fatigue | 3 | 2022 | 1555 | 0.640 |
Why?
|
Receptors, Fc | 3 | 2021 | 537 | 0.630 |
Why?
|
Receptors, Thrombopoietin | 3 | 2021 | 159 | 0.610 |
Why?
|
Glucosephosphate Dehydrogenase Deficiency | 1 | 2018 | 94 | 0.580 |
Why?
|
Premedication | 1 | 2018 | 245 | 0.560 |
Why?
|
Child, Preschool | 28 | 2024 | 42577 | 0.540 |
Why?
|
Piperazines | 4 | 2024 | 2547 | 0.540 |
Why?
|
Hemoglobins | 3 | 2022 | 1531 | 0.500 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 1560 | 0.500 |
Why?
|
Exchange Transfusion, Whole Blood | 1 | 2015 | 59 | 0.500 |
Why?
|
Hematologic Diseases | 1 | 2019 | 502 | 0.480 |
Why?
|
Erythrocytes | 3 | 2022 | 2412 | 0.480 |
Why?
|
Infant | 20 | 2024 | 36461 | 0.470 |
Why?
|
Disease Management | 7 | 2024 | 2533 | 0.460 |
Why?
|
Asparaginase | 2 | 2018 | 240 | 0.460 |
Why?
|
Neuroblastoma | 1 | 2022 | 1266 | 0.450 |
Why?
|
Recombinant Fusion Proteins | 2 | 2019 | 3738 | 0.420 |
Why?
|
Immunologic Factors | 4 | 2014 | 1594 | 0.410 |
Why?
|
Adolescent | 34 | 2024 | 88904 | 0.400 |
Why?
|
Humans | 87 | 2024 | 766766 | 0.380 |
Why?
|
Hematinics | 1 | 2014 | 282 | 0.370 |
Why?
|
Patient Care Planning | 1 | 2016 | 904 | 0.370 |
Why?
|
Pyrazoles | 5 | 2021 | 2030 | 0.370 |
Why?
|
Terminology as Topic | 2 | 2024 | 1540 | 0.360 |
Why?
|
Tacrolimus | 1 | 2014 | 753 | 0.360 |
Why?
|
Antisickling Agents | 1 | 2010 | 72 | 0.330 |
Why?
|
Cerebral Arterial Diseases | 1 | 2010 | 82 | 0.330 |
Why?
|
Erythropoietin | 1 | 2014 | 718 | 0.330 |
Why?
|
Immunization, Passive | 1 | 2011 | 618 | 0.330 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 696 | 0.320 |
Why?
|
Neutropenia | 1 | 2014 | 894 | 0.320 |
Why?
|
Hydroxyurea | 1 | 2010 | 284 | 0.310 |
Why?
|
Cost of Illness | 1 | 2018 | 1949 | 0.310 |
Why?
|
Adult | 31 | 2024 | 223307 | 0.300 |
Why?
|
Blood Transfusion | 3 | 2020 | 1308 | 0.300 |
Why?
|
Infant, Newborn | 10 | 2024 | 26389 | 0.290 |
Why?
|
Blood Platelets | 5 | 2022 | 2465 | 0.290 |
Why?
|
Bacterial Vaccines | 1 | 2009 | 400 | 0.280 |
Why?
|
Adrenal Cortex Hormones | 4 | 2020 | 1885 | 0.270 |
Why?
|
Skin | 1 | 2020 | 4499 | 0.270 |
Why?
|
Prednisone | 1 | 2011 | 1566 | 0.270 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2021 | 5753 | 0.260 |
Why?
|
Male | 43 | 2024 | 364142 | 0.250 |
Why?
|
Iron Chelating Agents | 2 | 2020 | 141 | 0.250 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 4215 | 0.250 |
Why?
|
Female | 42 | 2024 | 396520 | 0.250 |
Why?
|
Platelet Function Tests | 2 | 2018 | 275 | 0.240 |
Why?
|
Organ Transplantation | 1 | 2014 | 1172 | 0.230 |
Why?
|
Anticoagulants | 2 | 2018 | 4855 | 0.230 |
Why?
|
Thrombocytopenia, Neonatal Alloimmune | 1 | 2023 | 19 | 0.210 |
Why?
|
Genotype | 5 | 2024 | 13036 | 0.210 |
Why?
|
Antigens, Human Platelet | 1 | 2023 | 41 | 0.210 |
Why?
|
Scabies | 1 | 2002 | 14 | 0.200 |
Why?
|
Venous Thromboembolism | 2 | 2018 | 1882 | 0.200 |
Why?
|
Ivermectin | 1 | 2002 | 48 | 0.200 |
Why?
|
Hospitals, Pediatric | 1 | 2011 | 1851 | 0.190 |
Why?
|
Treatment Outcome | 16 | 2024 | 65273 | 0.190 |
Why?
|
Anemia, Sickle Cell | 1 | 2010 | 1063 | 0.190 |
Why?
|
Young Adult | 11 | 2024 | 59939 | 0.180 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2022 | 184 | 0.180 |
Why?
|
Insecticides | 1 | 2002 | 203 | 0.180 |
Why?
|
Chelation Therapy | 1 | 2020 | 76 | 0.170 |
Why?
|
Jaundice, Neonatal | 1 | 2020 | 70 | 0.170 |
Why?
|
Erythropoiesis | 1 | 2024 | 692 | 0.170 |
Why?
|
Erythrocytes, Abnormal | 1 | 2020 | 122 | 0.170 |
Why?
|
Splenomegaly | 1 | 2020 | 191 | 0.170 |
Why?
|
Tyrphostins | 1 | 2019 | 62 | 0.170 |
Why?
|
Catechols | 1 | 2019 | 63 | 0.170 |
Why?
|
Cholelithiasis | 1 | 2020 | 408 | 0.160 |
Why?
|
Patient Compliance | 1 | 2009 | 2694 | 0.160 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13643 | 0.160 |
Why?
|
Mutation | 6 | 2021 | 30213 | 0.160 |
Why?
|
Prospective Studies | 6 | 2022 | 54871 | 0.160 |
Why?
|
Prevalence | 3 | 2021 | 15835 | 0.150 |
Why?
|
Homozygote | 1 | 2023 | 1775 | 0.150 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4853 | 0.140 |
Why?
|
Laboratories | 1 | 2021 | 463 | 0.140 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14762 | 0.140 |
Why?
|
Helicobacter pylori | 1 | 2021 | 380 | 0.140 |
Why?
|
Helicobacter Infections | 1 | 2021 | 390 | 0.140 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 132 | 0.130 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15908 | 0.130 |
Why?
|
Retrospective Studies | 11 | 2023 | 81635 | 0.130 |
Why?
|
Gallstones | 1 | 2019 | 285 | 0.130 |
Why?
|
Toll-Like Receptor 4 | 1 | 2020 | 588 | 0.130 |
Why?
|
Cholecystectomy | 1 | 2018 | 409 | 0.130 |
Why?
|
Exanthema | 1 | 2020 | 502 | 0.130 |
Why?
|
Hemophilia B | 1 | 2006 | 83 | 0.130 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2020 | 621 | 0.120 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2016 | 119 | 0.120 |
Why?
|
Fetal Diseases | 1 | 2020 | 915 | 0.120 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2015 | 87 | 0.120 |
Why?
|
Communication | 4 | 2021 | 3905 | 0.120 |
Why?
|
Treatment Failure | 1 | 2021 | 2659 | 0.120 |
Why?
|
Scoliosis | 1 | 2021 | 793 | 0.110 |
Why?
|
Drug Resistance | 1 | 2020 | 1592 | 0.110 |
Why?
|
Heterozygote | 1 | 2020 | 2795 | 0.110 |
Why?
|
Reference Standards | 3 | 2021 | 1010 | 0.110 |
Why?
|
von Willebrand Diseases | 1 | 2015 | 135 | 0.110 |
Why?
|
Hypoglycemia | 1 | 2020 | 896 | 0.100 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 4860 | 0.100 |
Why?
|
Hemophilia A | 1 | 2006 | 359 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6895 | 0.100 |
Why?
|
Middle Aged | 13 | 2024 | 223257 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3110 | 0.100 |
Why?
|
Vaccines | 1 | 2021 | 842 | 0.100 |
Why?
|
Self Concept | 1 | 2018 | 1040 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3232 | 0.100 |
Why?
|
Ethyl Ethers | 1 | 2012 | 20 | 0.100 |
Why?
|
Phototherapy | 1 | 2015 | 368 | 0.100 |
Why?
|
Health Planning Guidelines | 1 | 2013 | 151 | 0.100 |
Why?
|
Enzyme Activation | 1 | 2018 | 3587 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7431 | 0.100 |
Why?
|
Perception | 1 | 2018 | 1204 | 0.100 |
Why?
|
Iron | 2 | 2018 | 1812 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1791 | 0.100 |
Why?
|
Spinal Fusion | 1 | 2021 | 1307 | 0.090 |
Why?
|
Administration, Oral | 1 | 2019 | 4018 | 0.090 |
Why?
|
Headache | 1 | 2019 | 1260 | 0.090 |
Why?
|
Comorbidity | 3 | 2024 | 10580 | 0.090 |
Why?
|
Registries | 3 | 2024 | 8351 | 0.090 |
Why?
|
von Willebrand Factor | 1 | 2015 | 680 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1667 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1926 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2590 | 0.090 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39309 | 0.090 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9244 | 0.090 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4114 | 0.080 |
Why?
|
Stem Cell Factor | 1 | 2000 | 194 | 0.080 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2019 | 1104 | 0.080 |
Why?
|
Activities of Daily Living | 1 | 2018 | 2429 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2254 | 0.080 |
Why?
|
Nausea | 1 | 2011 | 681 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6850 | 0.080 |
Why?
|
Thoracic Neoplasms | 1 | 2010 | 269 | 0.070 |
Why?
|
Consensus | 2 | 2022 | 3208 | 0.070 |
Why?
|
Cerebral Arteries | 1 | 2010 | 490 | 0.070 |
Why?
|
Quality Improvement | 1 | 2022 | 3850 | 0.070 |
Why?
|
Testis | 1 | 2000 | 786 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2009 | 15831 | 0.070 |
Why?
|
Emotions | 1 | 2018 | 2758 | 0.070 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12806 | 0.070 |
Why?
|
Constriction, Pathologic | 1 | 2010 | 1103 | 0.070 |
Why?
|
Pandemics | 3 | 2021 | 8735 | 0.060 |
Why?
|
Blood Flow Velocity | 1 | 2010 | 1374 | 0.060 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 2 | 2018 | 144 | 0.060 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1326 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8540 | 0.060 |
Why?
|
Lymphoma | 1 | 2015 | 1900 | 0.060 |
Why?
|
Birth Weight | 1 | 2014 | 2123 | 0.060 |
Why?
|
Medical Records | 1 | 2011 | 1408 | 0.060 |
Why?
|
Drug Utilization | 1 | 2011 | 1187 | 0.060 |
Why?
|
Survival Rate | 2 | 2019 | 12825 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2016 | 1659 | 0.060 |
Why?
|
Activin Receptors, Type I | 1 | 2005 | 133 | 0.060 |
Why?
|
Pregnancy | 3 | 2023 | 30237 | 0.060 |
Why?
|
Gestational Age | 1 | 2014 | 3617 | 0.060 |
Why?
|
Clinical Protocols | 1 | 2011 | 1437 | 0.060 |
Why?
|
Immunization | 1 | 2009 | 1218 | 0.060 |
Why?
|
Age Distribution | 1 | 2011 | 2869 | 0.060 |
Why?
|
Angiography | 1 | 2010 | 1595 | 0.060 |
Why?
|
Incidence | 2 | 2021 | 21525 | 0.060 |
Why?
|
International Cooperation | 1 | 2011 | 1434 | 0.060 |
Why?
|
Phenotype | 3 | 2018 | 16724 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2024 | 16044 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8045 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2023 | 22248 | 0.060 |
Why?
|
Thiazoles | 1 | 2012 | 1529 | 0.060 |
Why?
|
Decision Making | 1 | 2018 | 3951 | 0.060 |
Why?
|
P-Selectin | 2 | 2018 | 598 | 0.060 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2005 | 168 | 0.060 |
Why?
|
Time Factors | 2 | 2019 | 40149 | 0.060 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2018 | 577 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2015 | 3468 | 0.050 |
Why?
|
Radiography, Thoracic | 1 | 2010 | 1320 | 0.050 |
Why?
|
Recurrence | 2 | 2018 | 8507 | 0.050 |
Why?
|
Vanuatu | 1 | 2002 | 5 | 0.050 |
Why?
|
Heart Neoplasms | 1 | 2005 | 374 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2011 | 2158 | 0.050 |
Why?
|
Boston | 2 | 2011 | 9346 | 0.050 |
Why?
|
Cohort Studies | 3 | 2020 | 41710 | 0.050 |
Why?
|
Alanine | 1 | 2024 | 613 | 0.050 |
Why?
|
Chronic Disease | 2 | 2019 | 9357 | 0.050 |
Why?
|
Bacterial Infections | 1 | 2009 | 1390 | 0.050 |
Why?
|
Bone Diseases, Metabolic | 1 | 2024 | 407 | 0.040 |
Why?
|
Bone Density | 2 | 2024 | 3491 | 0.040 |
Why?
|
Physicians | 1 | 2018 | 4591 | 0.040 |
Why?
|
Hemolysis | 1 | 2022 | 417 | 0.040 |
Why?
|
Hematocrit | 1 | 2021 | 622 | 0.040 |
Why?
|
Asia | 1 | 2021 | 629 | 0.040 |
Why?
|
Age Factors | 2 | 2017 | 18397 | 0.040 |
Why?
|
Haploinsufficiency | 1 | 2020 | 334 | 0.040 |
Why?
|
Rare Diseases | 1 | 2023 | 630 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2020 | 349 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2022 | 12430 | 0.040 |
Why?
|
HLA Antigens | 1 | 2023 | 1339 | 0.040 |
Why?
|
Plasma Exchange | 1 | 2018 | 160 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 878 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2018 | 26310 | 0.030 |
Why?
|
Ultrasonography | 1 | 2010 | 5992 | 0.030 |
Why?
|
Pulmonary Embolism | 1 | 2010 | 2596 | 0.030 |
Why?
|
Factor IX | 1 | 2006 | 76 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2021 | 746 | 0.030 |
Why?
|
Prenatal Care | 1 | 2023 | 1158 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.030 |
Why?
|
Receptor, PAR-1 | 1 | 2015 | 109 | 0.030 |
Why?
|
Risk Factors | 3 | 2018 | 74881 | 0.030 |
Why?
|
Psychometrics | 1 | 2023 | 3060 | 0.030 |
Why?
|
Exons | 1 | 2020 | 2392 | 0.030 |
Why?
|
Factor VIII | 1 | 2006 | 349 | 0.030 |
Why?
|
Cell-Derived Microparticles | 1 | 2015 | 159 | 0.030 |
Why?
|
Scattering, Radiation | 1 | 2015 | 483 | 0.030 |
Why?
|
History, 21st Century | 1 | 2019 | 1574 | 0.030 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1604 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3624 | 0.030 |
Why?
|
Societies, Medical | 1 | 2024 | 3957 | 0.020 |
Why?
|
Remission Induction | 1 | 2017 | 2413 | 0.020 |
Why?
|
Hemoglobinopathies | 1 | 2012 | 101 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36567 | 0.020 |
Why?
|
Parents | 1 | 2024 | 3593 | 0.020 |
Why?
|
Prognosis | 1 | 2011 | 29948 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3434 | 0.020 |
Why?
|
Developing Countries | 1 | 2002 | 2913 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 903 | 0.020 |
Why?
|
Genetic Variation | 1 | 2024 | 6612 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 932 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2002 | 5536 | 0.020 |
Why?
|
Light | 1 | 2015 | 1358 | 0.020 |
Why?
|
Spermatogenesis | 1 | 2000 | 259 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2015 | 59550 | 0.020 |
Why?
|
Solubility | 1 | 2000 | 1078 | 0.020 |
Why?
|
Oxygen | 1 | 2020 | 4251 | 0.020 |
Why?
|
Spinal Cord | 1 | 2016 | 1811 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2015 | 1374 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 1997 | 1404 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 2015 | 1384 | 0.020 |
Why?
|
Bivalvia | 1 | 1997 | 55 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2006 | 2325 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 20708 | 0.020 |
Why?
|
Chromatography, Gel | 1 | 1997 | 634 | 0.020 |
Why?
|
Biopsy | 2 | 2005 | 6779 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2000 | 2275 | 0.020 |
Why?
|
Creatinine | 1 | 2012 | 1917 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20144 | 0.020 |
Why?
|
Incidental Findings | 1 | 2010 | 698 | 0.020 |
Why?
|
Activin Receptors, Type II | 1 | 2005 | 122 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5890 | 0.010 |
Why?
|
Genetic Linkage | 1 | 2010 | 2342 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10384 | 0.010 |
Why?
|
United States | 2 | 2024 | 72951 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4570 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 18075 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2015 | 5143 | 0.010 |
Why?
|
Pedigree | 1 | 2010 | 4539 | 0.010 |
Why?
|
Aged | 3 | 2015 | 171343 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7475 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15416 | 0.010 |
Why?
|
Cell Membrane | 1 | 2000 | 3641 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12985 | 0.010 |
Why?
|
Water | 1 | 1997 | 1417 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10745 | 0.010 |
Why?
|
Testosterone | 1 | 2000 | 2495 | 0.010 |
Why?
|
Protein Conformation | 1 | 1997 | 3947 | 0.010 |
Why?
|
Idarubicin | 1 | 1997 | 59 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2015 | 11651 | 0.010 |
Why?
|
Models, Molecular | 1 | 1997 | 5386 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 11872 | 0.010 |
Why?
|
Vidarabine | 1 | 1997 | 342 | 0.010 |
Why?
|
Liver | 1 | 2012 | 7571 | 0.010 |
Why?
|
Cytarabine | 1 | 1997 | 696 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2000 | 12791 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1997 | 633 | 0.010 |
Why?
|
Leukemia, Myeloid | 1 | 1997 | 695 | 0.010 |
Why?
|
Genomics | 1 | 2010 | 5923 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1997 | 1606 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2005 | 11061 | 0.010 |
Why?
|
Risk Assessment | 1 | 2010 | 24295 | 0.000 |
Why?
|
Acute Disease | 1 | 1997 | 7241 | 0.000 |
Why?
|
Animals | 2 | 2010 | 168930 | 0.000 |
Why?
|
Neutrophils | 1 | 1997 | 3782 | 0.000 |
Why?
|
Length of Stay | 1 | 1997 | 6490 | 0.000 |
Why?
|